Researchers at Washington University School of Medicine in St. Louis published the results of a clinical trial evaluating an antidepressant, fluvoxamine, for early treatment for Covid-19.
Luye Pharma Group submitted a new drug application to the U.S. Food and Drug Administration for LY03005, a new chemical drug for the treatment of major depressive disorder.
CVS Health Corp. and the drugstore chain’s Omnicare unit were sued by the U.S. government, which accused them of fraudulently billing Medicare and other programs for drugs for older and disabled people without valid prescriptions.
Sage Therapeutics Inc.’s experimental fast-acting drug aimed at treating severe depression failed a closely-watched study, sending shares down 60 percent and erasing about $4.6 billion of the drugmaker’s market value.
When major depressive disorder does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it’s reclassified as treatment-resistant depression (TRD). South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet the primary efficacy endpoints for TRD in a Phase II clinical trial.
The U.S. FDA rejected marketing approval of Alkermes’ major depressive disorder treatment ALKS-5461.
An FDA advisory panel voted against approving Alkermes Plc’s depression treatment ALKS 5461 in patients with an inadequate response to standard antidepressant therapies.
Researchers from Amen Clinics, Google, Johns Hopkins University, UCLA, and UC San Francisco studied 62,454 brain scans of more than 30,000 people to study brain aging.
Janssen, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray in patients with treatment-resistant depression.
A vast research study that sought to settle a long-standing debate about whether or not anti-depressant drugs really work has found they are indeed effective in relieving acute depression in adults.